Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention
Clear guidelines now map out when infections strike CAR T-cell therapy patients and which prevention strategies work best, helping clinicians protect this growing population.
This guideline-aligned review synthesizes current evidence on infectious complications following CAR T-cell therapy, detailing the evolving infection spectrum (early bacterial, late viral/opportunistic), risk factors by CAR-T product type, and structured prevention strategies. Clinically actionable and aligned with NCCN/ASH guidelines, it provides a practical framework for managing the growing population of CAR-T recipients.
What the study was
- Study design
- Narrative review with guideline synthesis
- Population
- Patients with B-cell malignancies receiving CAR T-cell therapy
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Blood Research
Why it surfaced
Clinically relevant guideline synthesis for an increasingly common therapy (CAR-T). Timely as BCMA-directed therapies are expanding. Review quality is good with NCCN 2026 guideline integration.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.